| 摘要 |
Novel morpholines and morpholine-N-oxides of the formula <IMAGE> in which A denotes an n-alkylene group which is optionally mono- or disubstituted by methyl or ethyl groups, X denotes a bond or an oxygen atom, R1 denotes a heteroaromatic 6-membered ring which is optionally substituted by a halogen atom or a trifluoromethyl or alkyl group, R2 denotes a hydrogen atom or a hydroxyl group, R3 denotes a hydroxyl, alkoxy, carboxyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl group, an alkoxy group which is substituted at the end by a hydroxyl, alkoxy, phenylalkoxy, carboxyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl group, or an ethenylene group which is optionally substituted by an alkyl group and which is substituted at the end by a carboxyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, pyrrolidino, piperidino or hexamethyleneimino group, and n denotes the number 0 or 1, their optical isomers, diastereomers and their acid addition salts. The novel compounds of the above formula I, their optical isomers and their diastereomers and also their acid addition salts, in particular their physiologically tolerable acid addition salts with inorganic or organic acids, have useful pharmacological properties, namely an action on the metabolism, preferably a hypoglycaemic and body fat-reducing action, and also a reducing action on the atherogenic beta -lipoproteins VLDL and LDL. They additionally have a performance-increasing action in animals. The novel compounds of the above formula I can be prepared by processes known per se. |
